BlinkLab Ltd
ASX:BB1
We don't have any information about BB1's insider trading.
BlinkLab Ltd
Glance View
An app that turns an ordinary mobile phone into a device for conducting objective neurobehavioral tests could make it easier and more cost-effective to diagnose neurological disorders. The company is headquartered in Sydney, New South Wales. The company went IPO on 2024-04-04. The Company’s tests include eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response, which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The BlinkLab Device (BlinkLab Dx) consists of BlinkLab App, a mobile application for patients, caregivers and/or parents, effectively a front-end tool that helps collect test subjects’ information and responses to the BlinkLab Tests in real time (BlinkLab App), and BlinkLab Portal, which includes a fully built secure database and content management system (CMS) as well as experimenter’s portal that allows for full customization of the neurometric tests as well as data analysis, annotation and visualization tools (the BlinkLab Portal).
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
